Sai Parenteral's IPO

The company proposes to expand and upgrade Units I, II, III and IV to enhance injectable and oral solid dosage manufacturing capabilities and align facilities with EU-GMP and PIC/S requirements. The expansion includes infrastructure development, installation of plant and machinery, quality control equipment, utilities and engineering systems.

The company proposes to establish a new R&D facility at Unit IV, Bollaram, Telangana, to be operated by subsidiary SP Analytics Private Limited. The facility will be designed to comply with international regulatory standards and will house formulation laboratories, analytical testing infrastructure, and pilot-scale manufacturing capabilities.

The company proposes to repay/prepay certain borrowings to reduce outstanding indebtedness, improve debt-equity ratio, and enable utilization of additional internal accruals for investment in business growth and expansion. This will strengthen the company's ability to raise further resources at competitive terms.

The company proposes to part-fund incremental working capital requirements arising from capacity expansion and upgradation of manufacturing facilities. Higher working capital will be required to finance larger volumes of raw material procurement, maintain higher inventory levels, and extend credit to a wider customer base.

The company proposes to repay bridge loan and term loan availed for investment in wholly owned subsidiary Sai Parenterals Pte Limited (Singapore) in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia). This acquisition supports the company's inorganic growth strategy in regulated markets.

The company intends to deploy any balance from Net Proceeds towards general corporate purposes including funding organic and inorganic growth opportunities, strengthening marketing capabilities, employee expenses, professional fees, and meeting ongoing corporate contingencies, subject to not exceeding twenty-five percent of Net Proceeds.